NICE Onpattro approval puts Alnylam back in hATTR running
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read More
Tag: hATTR
Final NICE guidance issued for Akcea’s Tegsedi
The drug should be available for routine use within 90 days for patients in England.
Read More
‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR
The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
Read More
NICE rejects NHS funding for Tegsedi, Onpattro
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read More
US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
Alnylam’s RNA therapy Onpattro bags EU nod
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.
Read More
EU approval for Akcea/Ionis’ rare disease therapy
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
Sanofi, Alnylam file hATTR amyloidosis therapy in the EU
Sanofi Genzyme and Alnylam Pharmaceuticals have submitted a marketing application to the European Medicines Agency for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
